fat graft

脂肪移植
  • 文章类型: Case Reports
    喉皮瘘(LCF)是全喉切除术后的严重并发症,显著影响患者的生活质量和治疗成本。管理是复杂的,手术干预后可能复发。
    方法:我们介绍一例喉切除术后出现的LCF。最初的保守治疗未能解决瘘管。然后尝试胸大肌肌筋膜皮瓣,但是瘘管复发了.最后,自体脂肪移植效果极佳.
    保守管理应该是LCF的第一线方法,因为大多数情况下反应良好。然而,如果瘘管持续存在,应探索替代方法以达到最佳结果。我们的案例强调了不坚持失败方法的重要性。自体脂肪移植提供了一个有希望的替代方案,具有明显的积极结果。
    结论:喉皮瘘在喉切除术后护理中提出了重大挑战。手术修复可能很复杂,有潜在的并发症。我们的案例证明了自体脂肪移植作为一种成功的治疗方式的有效性。
    UNASSIGNED: Pharyngocutaneous fistula (PCF) is a serious complication following total laryngectomy, significantly impacting patients\' quality of life and treatment costs. Management is complex, with potential for recurrence after surgical intervention.
    METHODS: We present a case of PCF that developed following laryngectomy. Initial conservative treatment failed to resolve the fistula. A pectoralis major myofascial flap was then attempted, but the fistula recurred. Finally, autologous fat grafting was performed with excellent results.
    UNASSIGNED: Conservative management should be the first-line approach for PCF, as most cases respond favorably. However, if the fistula persists, alternative methods should be explored to achieve optimal outcomes. Our case highlights the importance of not persisting with a failed approach. Autologous fat grafting offers a promising alternative with demonstrably positive outcomes.
    CONCLUSIONS: Pharyngocutaneous fistula presents a significant challenge in post-laryngectomy care. Surgical repair can be complex with potential complications. Our case demonstrates the effectiveness of autologous fat grafting as a successful treatment modality.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    唇裂修复后的常见问题是嘴唇体积不足和不吸引人的美学。自体脂肪移植是一种改善矫正后畸形外观的方法。这篇综述的目的是评估自体脂肪移植在改善唇裂畸形美学方面的有效性。脂肪干细胞(ADSC)的好处,脂肪移植的好处和并发症,嫁接的时机,将检查收获和移植技术。此审查过程使用“PubMed”和“GoogleScholar”作为主要数据库。使用关键术语组合进行搜索:“脂肪移植,\"\"唇裂,\"\"朱红色,\"\"自体脂肪移植,“和”脂肪细胞来源的干细胞。\"对其他相关数据的参考列表进行了审查。自体脂肪移植可以在初次修复期间进行或作为二次矫正。无论修复时机如何,在一些或所有测量变量中观察到外观的统计学显著改善。两种时机选择都显示出有利的结果;然而,有更多的证据支持移植作为二次矫正。一定程度的移植物再吸收会发生,为过度纠正以弥补损失的做法提供证据。移植物保留通过12个月标记稳定。移植物内ADSC的存在有助于移植物稳定和保留。尽管缺乏纵向数据来检查患者一生中的移植物保留,自体脂肪移植似乎是一种安全且微创的修复唇裂修复后继发畸形的方法,随访数据支持,随访数据为术后2年,报告的并发症最少.
    A frequent problem following cleft lip repair is insufficient lip volume and unappealing aesthetics. Autologous fat grafting is a method of improving the appearance of post-correction deformity. The aim of this review is to evaluate the effectiveness of autologous fat grafting in improving the aesthetics of cleft lip deformity. The benefits of adipose-derived stem cells (ADSCs), benefits and complications of fat grafting, timing of grafting, and harvest and transplant techniques will be examined. This review process used \"PubMed\" and \"Google Scholar\" as primary databases. Searches were performed using combinations of key terms: \"Fat Graft,\" \"Cleft Lip,\" \"Vermillion,\" \"Autologous Fat Transplantation,\" and \"Adipocyte Derived Stem Cell.\" Reviews of reference lists for additional pertinent data were performed. Autologous fat grafting may be performed during primary repair or as a secondary correction. Statistically significant improvements in appearance were observed in some or all measured variables regardless of repair timing. Both timing options show favorable outcomes; however, there is more evidence in support of grafting as a secondary correction. Some degree of graft reabsorption will occur, lending evidence to the practice of overcorrecting to accommodate losses. Graft retention is stabilized by the 12-month mark. The presence of ADSCs within the graft aids in graft stabilization and retention. Despite a lack of longitudinal data to examine graft retention throughout a patient\'s lifetime, autologous fat grafting appears to be a safe and minimally invasive method of repairing deformity secondary to cleft lip repair supported by follow-up data as far as two years postoperatively with minimal reported complications.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:脱发可能通过限制患者的社交生活来降低患者的生活质量和自信心。因此,治疗的主要目标是限制或阻止炎症的进展,疤痕,和脱发。脂肪注射对头发再生的有希望的效果,有限的不利影响,消退的炎症可以证明其治疗脱发的有效性和安全性。
    目的:本综述旨在评估自体脂肪组织注射在瘢痕和非瘢痕性脱发中的作用。
    方法:因此,在科学网上进行了彻底的搜索,Scopus,和PubMed/Medline数据库,以及谷歌学者搜索引擎,对于从开始到9月1日发表的研究,2023年,使用相关关键字。
    结果:自体脂肪移植(AFG)是治疗脱发的一种新颖且潜在有效的方法,特别是原发性和继发性瘢痕性脱发。AFG可以是治疗难治性扁平苔藓的有效半侵入性选择,因为它诱导血管生成,支持头发再生。除了瘢痕性脱发,AFG有望治疗非瘢痕性脱发,包括雄激素性脱发和斑秃。脂肪组织(AT)中的脂肪再生细胞(ADRCs)分泌不同的生长因子,进一步支持头发再生。此外,在AT中已知不同的抗炎剂和抗氧化剂,防止毛囊进一步受损。
    结论:AFG可以显著控制炎症过程,改善症状和体征,并增加头发密度和直径。
    BACKGROUND: Alopecia may decrease patients\' quality of life and self-confidence by limiting their social life. Therefore, the main goal of the treatment is to limit or halt the progression of inflammation, scarring, and hair loss. The promising effect of fat injection on hair regrowth, limited adverse effects, and subsiding inflammation can be proof of its efficacy and safety in treating alopecia.
    OBJECTIVE: This review sought to assess the role of autologous fat tissue injection in scarring and non-scarring alopecia.
    METHODS: Accordingly, a thorough search was performed on the Web of Science, Scopus, and PubMed/Medline databases, as well as the Google Scholar search engine, for studies published from inception until September 1st, 2023, using the related keywords.
    RESULTS: Autologous fat grafting (AFG) is a novel and potentially effective modality for treating alopecia, particularly primary and secondary cicatricial alopecia. AFG can be an effective semi-invasive option for treating refractory lichen planopilaris because it induces angiogenesis, which supports hair regrowth. In addition to cicatricial alopecia, AFG held promise for treating non-scarring alopecia, including androgenic alopecia and alopecia areata. The adipose-derived regenerative cells (ADRCs) in adipose tissue (AT) secrete different growth factors, further supporting hair regeneration. Moreover, different anti-inflammatory and anti-oxidative agents are known in AT, preventing further damage to hair follicles.
    CONCLUSIONS: AFG can significantly control inflammatory processes, improve signs and symptoms, and increase hair density and diameter.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    Nanofat是一种相对新颖的脂肪移植技术,在再生医学领域获得了极大的兴趣,美学和翻译研究。它涉及从患者体内提取自体脂肪,然后转化为“nanofat”,由直径小于0.1毫米的小脂肪颗粒组成,含有高浓度的干细胞和生长因子。本文重点介绍了纳米脂肪在面部年轻化中的应用及其对脂肪模型化的潜力。脂肪组织是一种“干细胞储库”,纳米脂肪含有许多可以分化为各种细胞类型的干细胞。Lipogem技术,开发于2013年,能够隔离具有完整血管周围结构的纳米脂肪,利用脂肪血管系统周细胞附近高浓度的间充质基质细胞。如今,纳米脂肪主要用于美容目的,特别是在恢复活力和改善皮肤的外观,尤其是脸。的确,它具有广泛的适用性;它可以用来处理细纹,皱纹,痤疮疤痕,晒伤的皮肤,疤痕修复,作为脱发治疗。然而,需要进一步的研究来评估该技术的长期疗效和安全性.总之,nanofat是一种安全和微创的组织再生选择,具有相当大的治疗潜力。本研究综述了纳米脂肪在再生医学和面部美容手术中的应用及效果。
    Nanofat is a relatively novel technique in fat grafting that has gained significant interest in the fields of regenerative medicine, aesthetic and translational research. It involves the extraction of autologous fat from a patient, which is then transformed into \"nanofat\", consisting of small fat particles with a diameter of less than 0.1 mm and containing high concentrations of stem cells and growth factors. This article focuses on the use of nanofat in facial rejuvenation and its potential for lipomodelling. Fat tissue is a \"stem cell depot\" and nanofat contains many stem cells that can differentiate into various cell types. The Lipogem technology, developed in 2013, enables the isolation of nanofat with an intact perivascular structure, utilizing the high concentration of mesenchymal stromal cells near the pericytes of the adipose vascular system. Nowadays nanofat is used primarily for cosmetic purposes particularly in rejuvenating and improving the appearance of the skin, especially the face. Indeed, it has wide applicability; it can be used to treat fine lines, wrinkles, acne scars, sun-damaged skin, scar repair, and as an alopecia treatment. However, further studies are needed to assess the long-term efficacy and safety of this technique. In conclusion, nanofat is a safe and minimally invasive option for tissue regeneration with considerable therapeutic potential. This study reviews the application and effects of nanofat in regenerative medicine and facial cosmetic surgery.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    迄今为止,很少有研究研究脂肪干细胞(ADSC)在糖尿病足溃疡(DFU)患者中的作用。我们的目的是对文献进行系统的搜索,以探索在DFU患者中应用ADSCs背后的可用证据,以确定在该患者队列中,关于治愈率和愈合时间是否有任何额外的益处。在PubMed和Embase数据库中搜索符合条件的研究。只有研究单独ADSCs对DFU愈合影响的随机对照试验被认为是合格的,并被纳入审查。报告的治愈率,收集并分析愈合时间和手术相关并发症.最初的搜索结果是160篇论文。重复删除后,对131篇论文进行了资格筛选。只有四项试验符合研究标准,并被纳入最终审查和分析。纳入四项研究的189名患者中有97名接受ADSCs治疗DFU,其余92名患者接受标准措施(对照)。参与者年龄中位数为62岁,主要为男性(72.5%)。在12个月时,ADSC组83.5%(n=81)的患者完全愈合,而对照组为52%(n=48)(OR=4.8,95CI=2.25~10.24,P<0.0001)。ADSC组的平均愈合时间为31至85天,而对照组的平均愈合时间为42至85天(合并加权平均差=-10.832856,95CI=-22.44至0.77,P=0.0673)。两组均无明显手术相关并发症。在DFU患者中使用ADSC似乎显示出提高的治愈率。根据初步报告,ADSC的收获和给药程序似乎是安全的。大,需要随机试验来确定其在糖尿病足伤口患者中的作用.
    Few studies to date have investigated the role of adipose derived stem cells (ADSCs) in patients with diabetic foot ulcers (DFU). We aimed to conduct a systematic search of the literature to explore the available evidence behind ADSCs application in patients with DFU to establish if it has any added benefit regarding healing rate and healing time in this cohort of patients. The PubMed and Embase databases were searched for eligible studies. Only randomised controlled trials which investigated the impact of ADSCs alone on the healing of DFU were considered eligible and were included for the review. Reported healing rates, time to healing and procedure related complications were collected and analysed. The initial search resulted in 160 papers. Following duplicate removal, 131 papers were screened for eligibility. Only four trials met the study criteria and were included for the final review and analysis. 97 out of 189 patients who were included in the four studies received ADSCs for treatment of DFU whereas the remaining 92 patients received standard measures (control). The median participant age was 62, predominantly male (72.5%). Complete healing was achieved in 83.5% (n  =  81) of patients in the ADSC group compared to 52% (n  =  48) for patients in the control group at 12 months (OR = 4.8, 95%CI  =  2.25 to 10.24, P < 0.0001). Mean healing time in the ADSC group ranged from 31 to 85 days whereas mean healing time in the control group ranged from 42 to 85 days (Pooled weighted mean difference  =  -10.832856, 95%CI  =  -22.44 to 0.77, P  =  0.0673). No significant procedure related complications were reported in either group. The use of ADSCs in patients with DFU appears to demonstrate improved healing rates. The procedure of ADSC harvest and administration appears to be safe based on the initial reports. Large, randomised trials are needed to establish its role in patients with diabetic foot wounds.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Systematic Review
    背景:自体脂肪移植(AFG)是重建和整容手术中的通用技术。移植物处理是导致临床结果不可靠的变异性的关键来源。在最优方法上没有达成共识。本系统综述确定了支持不同处理范式的证据基础。
    方法:使用PubMed进行了系统的文献检索,Scopus和Cochrane基金会数据库。确定了比较AFG处理方法和报告长期患者结果的研究。
    结果:确定了24项研究(2413例患者)。评估的加工技术包括离心,倾析,washing,过滤,纱布轧制,以及商业设备和脂肪来源的干细胞/基质细胞(ASC)富集方法。讨论了客观体积和主观患者报告的结果。有一个可变的并发症和体积保留率的报告。并发症很少;明显的囊肿(0-20%),手术部位感染(0-8%)和脂肪坏死(0-58.4%)报告最多.在AFG的乳房中,技术之间的长期体积保留没有显着差异。在头颈部患者中,与离心(31.8-76%)相比,ASC富集(64.8-95%)和商业设备(41.2%)的体积保留更大.
    结论:通过洗涤和过滤进行接枝处理,包括并入商业设备时,与离心和倾析方法相比,长期结果优越。ASC富集方法和商业装置似乎在面部脂肪移植中具有优异的长期体积保留。
    Autologous fat grafting (AFG) is a versatile technique in reconstructive and cosmetic surgery. Graft processing is a key source of variability resulting in unreliable clinical outcomes, with no consensus on the optimal methodology. This systematic review identifies the evidence base supporting different processing paradigms.
    A systematic literature search was conducted using the PubMed, Scopus and The Cochrane Foundation databases. Studies comparing AFG processing methods and reporting long-term patient outcomes were identified.
    Twenty-four studies (2413 patients) were identified. Processing techniques evaluated included centrifugation, decantation, washing, filtration, gauze rolling, as well as commercial devices and adipose-derived stem/stromal cell (ASC) enrichment methods. Objective volumetric and subjective patient-reported outcomes were discussed. There was a variable reporting of complications and volume retention rates. Complications were infrequent; palpable cysts (0-20%), surgical-site infections (0-8%) and fat necrosis (0-58.4%) were the most reported. No significant differences in long-term volume retention between techniques were found in AFG in the breast. In head and neck patients, greater volume retention was documented in ASC enrichment (64.8-95%) and commercial devices (41.2%) compared to centrifugation (31.8-76%).
    Graft processing through washing and filtration, including when incorporated into commercial devices, results in superior long-term outcomes compared to centrifugation and decantation methods. ASC enrichment methods and commercial devices seem to have superior long-term volume retention in facial fat grafting.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    目的内镜下经蝶窦手术(TSS)后脑脊液(CSF)泄漏仍然是一个挑战,并与高发病率相关。我们在垂体fossa中使用fat进行初次修复,并在s蝶窦(FFS)中进一步增加脂肪。我们将这种FFS技术与其他修复方法的疗效进行了比较,并进行了系统评价。设计,患者,和方法回顾性分析2009年至2020年接受标准TSS的患者,比较使用FFS技术与其他术中修复策略相比,术后明显的CSF鼻漏(需要干预)的发生率。根据系统评价和荟萃分析(PRISMA)指南的首选报告项目,对文献中描述的当前修复方法进行了系统评价。结果在所有,有439名患者,276例患者接受多层修复,68例患者FFS修复,95名患者无法修复。两组之间的基线人口统计学没有观察到显着差异。与多层修复组(20.3%)和无修复组(12.6%,p<0.01)。这转化为更少的再操作(2.9%的FFS与13.4%多层与8.4%无修复,p<0.05),腰椎排水沟减少(2.9%FFSvs.15.6%多层与5.3%无修复,p<0.01),住院时间较短(中位天数:4[3-7]FFSvs.6(5-10)多层与5(3-7)无维修,p<0.01)。术后渗漏的危险因素包括女性,围手术期腰椎引流,术中渗漏。结论标准内镜经蝶入路自体脂肪移植可有效降低术后脑脊液明显渗漏的风险,减少再次手术,缩短住院时间。
    Objectives  Cerebrospinal fluid (CSF) leak following endoscopic transsphenoidal surgery (TSS) remains a challenge and is associated with high morbidity. We perform a primary repair with f at in the pituitary f ossa and further fat in the s phenoid sinus (FFS). We compare the efficacy of this FFS technique with other repair methods and perform a systematic review. Design, Patients, and Methods  This is a retrospective analysis of patients undergoing standard TSS from 2009 to 2020, comparing the incidence of significant postoperative CSF rhinorrhea (requiring intervention) using the FFS technique compared with other intraoperative repair strategies. Systematic review of current repair methods described in the literature was performed following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. Results  In all, there were 439 patients, with 276 patients undergoing multilayer repair, 68 patients FFS repair, and 95 patients no repair. No significant differences were observed in baseline demographics between the groups. Postoperative CSF leak requiring intervention was significantly lower in the FFS repair group (4.4%) compared with the multilayer (20.3%) and no repair groups (12.6%, p  < 0.01). This translated to fewer reoperations (2.9% FFS vs. 13.4% multilayer vs. 8.4% no repair, p  < 0.05), fewer lumbar drains (2.9% FFS vs. 15.6% multilayer vs. 5.3% no repair, p  < 0.01), and shorter hospital stay (median days: 4 [3-7] FFS vs. 6 (5-10) multilayer vs. 5 (3-7) no repair, p  < 0.01). Risk factors for postoperative leak included female gender, perioperative lumbar drain, and intraoperative leak. Conclusion  Autologous fat on fat graft for standard endoscopic transsphenoidal approach effectively reduces the risk of significant postoperative CSF leak with reduced reoperation and shorter hospital stay.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Systematic Review
    背景:克罗恩的肛周瘘通常难以进行标准治疗。假设脂肪移植物注射可提高瘘管愈合率。我们在系统评价(PRISMA)中评估了脂肪移植注射治疗克罗恩肛周瘘的疗效。
    方法:我们完成了MEDLINE(Ovid)的数据库搜索,Embase,和PubMed。所有以英文全文或摘要发表的研究,从2001年1月至2021年8月,我们选择了接受脂肪移植注射治疗克罗恩肛周瘘的方法。纳入随机对照试验,单臂干预试验,队列研究,和病例系列;排除单个病例报告。主要结果是汇集临床愈合,定义为非引流治疗的瘘管,或关闭,定义为治疗的瘘管闭合。次要结果是临床愈合,临床闭合,放射学反应,和不良事件。
    结果:在确定的1258种出版物中,891篇文章被评估为合格,和107相关的稿件审查。在四个单臂干预试验中,49名患者接受了克罗恩肛周瘘的脂肪移植注射。在汇总的单臂荟萃分析中,临床愈合或闭合率为74%(95%置信区间:57%,85%),研究之间具有中等异质性。在3个月和12个月时,临床愈合分别达到20%和60%,分别。6个月时临床闭合率为83%。可变参数用于定义放射学反应,成功率从20%到67%。报告了最小的不良事件。
    结论:在本系统综述和荟萃分析中,脂肪移植注射有望成为克罗恩肛周瘘的新治疗方法。对照匹配研究的评估是必要的。
    Crohn\'s perianal fistulas are often refractory to standard management. Fat graft injections are hypothesised to improve fistula healing rates. We evaluated the treatment efficacy of fat graft injections for Crohn\'s perianal fistulas in a systematic review (PRISMA).
    We completed database searches of MEDLINE (Ovid), Embase, and PubMed. All studies published in English in full text or abstract, from January 2001 to August 2021, evaluating fat graft injections for Crohn\'s perianal fistulas were selected. Included randomized controlled trials, single-arm intervention trials, cohort studies, and case series; excluded single case reports. Primary outcome was pooled clinical healing, defined as non-draining treated fistulas, or closure, defined as closure of treated fistulas. Secondary outcomes were clinical healing, clinical closure, radiologic response, and adverse events.
    Of 1258 publications identified, 891 articles were assessed for eligibility, and 107 relevant for manuscript review. Forty-nine patients received fat graft injections for Crohn\'s perianal fistulas across four single-arm intervention trials. Clinical healing or closure was achieved in 74% in a pooled single-arm meta-analysis (95% confidence interval: 57%, 85%), with moderate heterogeneity between studies. Clinical healing was achieved in 20% and 60% at 3 and 12 months, respectively. Clinical closure was achieved in 83% at 6 months. Variable parameters were used to define radiologic response, with success rates from 20% to 67%. Minimal adverse events were reported.
    Fat graft injections show promise as a novel treatment for Crohn\'s perianal fistulas in this systematic review and meta-analysis. Assessment in controlled matched studies is warranted.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Systematic Review
    目的:很少有研究报道脂肪干细胞(ADSCs)支持下肢静脉性溃疡(VLU)患者愈合的安全性和持久性。为了确定是否有任何证据支持在VLU患者中使用ADSC,进行了系统审查。
    方法:按照PRISMA指南进行系统评价。检索PubMed和Embase数据库中的相关论文。对检索到的论文的参考文献进行了审查,以确定任何额外的合格研究。
    结果:重复删除后,根据标题和摘要筛选了950篇论文的资格,其中932篇被排除在外。最终分析包括四篇论文(一项随机研究和三项非随机研究)。总共66例患者接受ADSCs用于VLU治疗。唯一的随机论文报道了ADSC的6个月治愈率为75%,而对照组为50%。在一项研究中实现了100%的愈合。其余2项研究报告了25%和58%的愈合;然而,其中包括VLU相对较大的患者.据报道,应用ADSCs后疼痛评分降低。未报告与手术相关的严重并发症。
    结论:ADSCs可以促进慢性VLU患者的溃疡愈合,并且根据初步报告显示是安全的。大,需要随机试验来明确确定该技术在VLU患者中的作用.
    OBJECTIVE: Few studies have reported on the safety and durability of adipose-derived stem cells (ADSCs) to support healing in patients with venous leg ulcers (VLU). To establish if there is any evidence to support ADSC use in VLU patients, a systematic review was conducted.
    METHODS: A systematic review was conducted following the PRISMA guidelines. PubMed and Embase databases were searched for relevant papers. References from retrieved papers were reviewed to identify any extra eligible studies.
    RESULTS: After duplicate removal, 950 papers were screened for eligibility of which 932 were excluded based on title and abstract. Four papers were included in the final analysis (one randomised study and three non-randomised studies). 66 patients in total received ADSCs for VLU treatment. The only randomised paper reported 6-month healing rates of 75% with ADSCs compared to 50% in controls. 100% healing was achieved in one study. The remaining 2 studies reported 25% and 58% healing; however, they included patients with relatively large VLUs. Pain scores decreased after ADSCs application where reported. No serious procedure related complications were reported.
    CONCLUSIONS: ADSCs may enhance ulcer healing in patients with chronic VLU and appears safe based on initial reports. Large, randomised trials are needed to definitively establish the technique\'s role in VLU patients.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    Stromal vascular fraction (SVF) containing adipose stem cells (ASCs) has been used for many years in regenerative plastic surgery for autologous applications, without any focus on their potential allogenic role. Allogenic SVF transplants could be based on the possibility to use decellularized extracellular matrix (ECM) as a scaffold from a donor then re-cellularized by ASCs of the recipient, in order to develop the advanced therapy medicinal products (ATMP) in fully personalized clinical approaches. A systematic review of this field has been realized in accordance with the Preferred Reporting for Items for Systematic Reviews and Meta-Analyses-Protocols (PRISMA-P) guidelines. Multistep research of the PubMed, Embase, MEDLINE, Pre-MEDLINE, PsycINFO, CINAHL, Clinicaltrials.gov, Scopus database, and Cochrane databases has been conducted to identify articles and investigations on human allogenic ASCs transplant for clinical use. Of the 341 articles identified, 313 were initially assessed for eligibility on the basis of the abstract. Of these, only 29 met all the predetermined criteria for inclusion according to the PICOS (patients, intervention, comparator, outcomes, and study design) approach, and 19 have been included in quantitative synthesis (meta-analysis). Ninety-one percent of the studies previously screened (284 papers) were focused on the in vitro results and pre-clinical experiments. The allogenic use regarded the treatment of perianal fistulas, diabetic foot ulcers, knee osteoarthritis, acute respiratory distress syndrome, refractory rheumatoid arthritis, pediatrics disease, fecal incontinence, ischemic heart disease, autoimmune encephalomyelitis, lateral epicondylitis, and soft tissue defects. The information analyzed suggested the safety and efficacy of allogenic ASCs and ECM transplants without major side effects.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

公众号